Document Detail


Pancreatic cancer stem cells: emerging target for designing novel therapy.
MedLine Citation:
PMID:  22445908     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the past few years, there have been significant advances in the research on cancer stem cells (CSCs). The emerging evidences have demonstrated that CSCs and epithelial-mesenchymal transition (EMT)-type cells, which share molecular characteristics with CSCs, play critical roles in drug resistance, invasion, and metastasis. Pancreatic cancer (PC) has a high mortality due to both intrinsic (de novo) and extrinsic (acquired) drug resistance, leading to increased invasive and metastatic potential of PC cells. Therefore, targeting pancreatic CSCs and EMT-type cells could be a novel therapeutic strategy for the treatment of PC. In this article, we will review the current state of our knowledge on the role of pancreatic CSCs and EMT-type cells, and summarize the novel therapeutic strategies that could target pancreatic CSCs and EMT-type cells, leading to the reversal of EMT phenotype, the induction of drug sensitivity, and the inhibition of invasion and metastasis of PC, which is expected to yield better treatment outcome.
Authors:
Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Related Documents :
22863708 - Design, synthesis and anticancer activity of 4-morpholinothieno[3,2-d]pyrimidine deriva...
1551368 - Fine-needle aspiration cytology of multicystic mesothelioma.
22409218 - Exocyst subunits are involved in isoproterenol-induced amylase release from rat parotid...
22510488 - The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and a...
6094598 - Recovery of cyclic nucleotide regulation in protein-kinase-defective adrenal cells thro...
10101128 - Cell cycle-dependent sequencing of cell fate decisions in caenorhabditis elegans vulva ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-03-20
Journal Detail:
Title:  Cancer letters     Volume:  338     ISSN:  1872-7980     ISO Abbreviation:  Cancer Lett.     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-08-26     Completed Date:  2013-11-06     Revised Date:  2014-10-16    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  94-100     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm / drug effects,  genetics
Epithelial-Mesenchymal Transition / drug effects*,  genetics
Humans
Models, Genetic
Molecular Targeted Therapy / methods
Neoplastic Stem Cells / drug effects*,  metabolism,  pathology
Pancreatic Neoplasms / drug therapy*,  genetics,  pathology
Signal Transduction / drug effects,  genetics
Grant Support
ID/Acronym/Agency:
1R01CA154321/CA/NCI NIH HHS; 5R01CA083695/CA/NCI NIH HHS; 5R01CA108535/CA/NCI NIH HHS; 5R01CA131151/CA/NCI NIH HHS; 5R01CA132794/CA/NCI NIH HHS; R01 CA131151/CA/NCI NIH HHS; R01 CA131151-05/CA/NCI NIH HHS; R01 CA132794/CA/NCI NIH HHS; R01 CA132794-05/CA/NCI NIH HHS; R01 CA154321/CA/NCI NIH HHS; R01 CA154321-02/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Featuring the special issue editor: Associate Professor Alexandros G. Georgakilas.
Next Document:  Human breast and melanoma cancer stem cells biomarkers.